Last reviewed · How we verify
NCT06814275
Project neuroARTEMIS
NA trial testing ARTEMIS in Stimulant Use in 189 participants. Currently enrolling.
31 May 2028
Quick facts
| Lead sponsor | Wake Forest University Health Sciences |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 189 |
| Start date | 29 April 2025 |
| Primary completion | 31 May 2028 |
| Estimated completion | 31 December 2028 |
| Sites | 1 location across United States |
Drugs / interventions tested
- ARTEMIS
- Contingency management for Antiretroviral (ARV) adherence
Conditions studied
- Stimulant Use — all drugs for Stimulant Use →
- Human Immunodeficiency Virus (HIV) — all drugs for Human Immunodeficiency Virus (HIV) →
- Depression — all drugs for Depression →
Sponsor
Wake Forest University Health Sciences
Who can join
Adults 18 to 59, any sex, with Stimulant Use or Human Immunodeficiency Virus (HIV). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this research is to understand how chronic stress affects the way our brain and immune systems function, and in turn how this affects the way people feel, think, and behave. By learning more about how these processes work, the hope is to be able to develop better treatments to help with problems like depression and substance use. This study is intended for individuals that are HIV positive, currently taking prescription antiretroviral medications, and use stimulants. Through this intervention, the aim is to determine if this positive affect intervention can lead to reductions in stimulant use and depressed mood.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06814275
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Stimulant Use
Currently open trials in the same condition.
- NCT05835921 — Enhancing Prospective Thinking in Early Recovery · NA · recruiting
- NCT04899024 — PrEP Affect Regulation Treatment Innovation · NA · active not recruiting
- NCT04426214 — Neuromodulation and Cognitive Training for Substance Use Disorders · NA · recruiting
- NCT03935646 — Acute Effects of Stimulant Medication in College Students With ADHD · Phase 2 · recruiting
- NCT03470480 — rTMS for Craving in Methamphetamine Use Disorder · NA · recruiting
Other Wake Forest University Health Sciences trials
Trials by the same sponsor.
- NCT07474090 — Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial · NA · not yet recruiting
- NCT07282444 — A New Way to Share Radiation Therapy Plans Between Doctors, CORRECT Trial · NA · not yet recruiting
- NCT06876896 — Intra-abdominal Pressure (IAP) During PFA Treatment of A-fib/ A-Flutter · NA · recruiting
- NCT07227051 — Optimizing Self-Monitoring Feedback Delivery for the Treatment of Overweight and Obesity · NA · recruiting
- NCT07215624 — Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06814275 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Wake Forest University Health Sciences
- Last refreshed: 11 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06814275.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing